A case-control study on immunologic markers of patients with vitiligo

Vitiligo is a depigmentation skin disease often coexisting with other autoimmune disorders. The prevalence is 0.5–2 % of the world's population. A combination of genetic, environmental and biochemical factors play a role in pathogenesis of the disease. The aim of the study was to measure select...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2022-12, Vol.156, p.113785-113785, Article 113785
Hauptverfasser: Nieradko-Iwanicka, Barbara, Przybylska, Daria, Borzęcki, Andrzej
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 113785
container_issue
container_start_page 113785
container_title Biomedicine & pharmacotherapy
container_volume 156
creator Nieradko-Iwanicka, Barbara
Przybylska, Daria
Borzęcki, Andrzej
description Vitiligo is a depigmentation skin disease often coexisting with other autoimmune disorders. The prevalence is 0.5–2 % of the world's population. A combination of genetic, environmental and biochemical factors play a role in pathogenesis of the disease. The aim of the study was to measure selected cytokines in the blood sera of patients with vitiligo and to select the best marker of the disease. The study was conducted on 50 patients with vitiligo and 38 controls. The type of vitiligo, body surface area (BSA), disease advancement assessment according to Vitiligo European Task Force, the degree of skin involvement and degree of progression were measured. Patients' skin phototype was determined according to Fitzpatrick’s classification. Medical history was recorded. Venous blood samples were obtained, The sera were used for laboratory test. Determinations of IL-17, IL-22 and IL-23 were performed using the enzyme-linked immunoabsorbent assay. In the study group 4 cases had phototype I, 38 II, 8 III. In the control group: 3, 29, 6, respectively. Universal vitiligo was found in 38 patients, segmental in 2, acro-facial in 10. In all cases VETF was + 1. Hypothyroidism was recorded in the medical histories of 11 cases vs 2 controls. Significantly higher concentrations of IL-22 and IL-23 were in cases vs controls. IL-22 concentrations were significantly higher in the study group with BSA ≤ 10 than in the control group, and in the group with BSA ≥ 10 they were the highest (p 
doi_str_mv 10.1016/j.biopha.2022.113785
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2725445133</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S075333222201174X</els_id><sourcerecordid>2725445133</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-ad9bf90bfea0cb0fb4328f41c1bd37c61ac773d409faf150da8a949cef6709b63</originalsourceid><addsrcrecordid>eNp9kL1OwzAYRS0EEqXwBgweWRI-20mcLEhVVX6kSiwwW45jty5JHGynqG9PqjAz3eXeK52D0D2BlAApHg9pbd2wlykFSlNCGC_zC7QgVQ5JAcAv0QJ4zhLGKL1GNyEcACAvWLlAmxVWMuhEuT561-IQx-aEXY9t1429a93OKtxJ_6V9wM7gQUar-xjwj417fLTRtnbnbtGVkW3Qd3-5RJ_Pm4_1a7J9f3lbr7aJYiSPiWyq2lRQGy1B1WDqjNHSZESRumFcFUQqzlmTQWWkITk0spRVViltCg5VXbAleph_B---Rx2i6GxQum1lr90YBOU0z7KcMDZVs7mqvAvBayMGbyeQkyAgztbEQczWxNmamK1Ns6d5pieMo9VeBDUBK91Yr1UUjbP_H_wCvfB4jA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2725445133</pqid></control><display><type>article</type><title>A case-control study on immunologic markers of patients with vitiligo</title><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Nieradko-Iwanicka, Barbara ; Przybylska, Daria ; Borzęcki, Andrzej</creator><creatorcontrib>Nieradko-Iwanicka, Barbara ; Przybylska, Daria ; Borzęcki, Andrzej</creatorcontrib><description>Vitiligo is a depigmentation skin disease often coexisting with other autoimmune disorders. The prevalence is 0.5–2 % of the world's population. A combination of genetic, environmental and biochemical factors play a role in pathogenesis of the disease. The aim of the study was to measure selected cytokines in the blood sera of patients with vitiligo and to select the best marker of the disease. The study was conducted on 50 patients with vitiligo and 38 controls. The type of vitiligo, body surface area (BSA), disease advancement assessment according to Vitiligo European Task Force, the degree of skin involvement and degree of progression were measured. Patients' skin phototype was determined according to Fitzpatrick’s classification. Medical history was recorded. Venous blood samples were obtained, The sera were used for laboratory test. Determinations of IL-17, IL-22 and IL-23 were performed using the enzyme-linked immunoabsorbent assay. In the study group 4 cases had phototype I, 38 II, 8 III. In the control group: 3, 29, 6, respectively. Universal vitiligo was found in 38 patients, segmental in 2, acro-facial in 10. In all cases VETF was + 1. Hypothyroidism was recorded in the medical histories of 11 cases vs 2 controls. Significantly higher concentrations of IL-22 and IL-23 were in cases vs controls. IL-22 concentrations were significantly higher in the study group with BSA ≤ 10 than in the control group, and in the group with BSA ≥ 10 they were the highest (p &lt; 0.05). IL-22 is the best marker of active universal type vitiligo, it is directly proportional to the extent of lesions. [Display omitted] •IL-22 is the best marker of active universal type vitiligo.•IL-23 is elevated in patients with vitiligo.•The concentration of Il-22 is directly proportional to the area of skin affected.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2022.113785</identifier><language>eng</language><publisher>Elsevier Masson SAS</publisher><subject>Interleukin 17 ; Interleukin 22 ; Interleukin 23 ; Vitiligo</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2022-12, Vol.156, p.113785-113785, Article 113785</ispartof><rights>2022 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c315t-ad9bf90bfea0cb0fb4328f41c1bd37c61ac773d409faf150da8a949cef6709b63</citedby><cites>FETCH-LOGICAL-c315t-ad9bf90bfea0cb0fb4328f41c1bd37c61ac773d409faf150da8a949cef6709b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2022.113785$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Nieradko-Iwanicka, Barbara</creatorcontrib><creatorcontrib>Przybylska, Daria</creatorcontrib><creatorcontrib>Borzęcki, Andrzej</creatorcontrib><title>A case-control study on immunologic markers of patients with vitiligo</title><title>Biomedicine &amp; pharmacotherapy</title><description>Vitiligo is a depigmentation skin disease often coexisting with other autoimmune disorders. The prevalence is 0.5–2 % of the world's population. A combination of genetic, environmental and biochemical factors play a role in pathogenesis of the disease. The aim of the study was to measure selected cytokines in the blood sera of patients with vitiligo and to select the best marker of the disease. The study was conducted on 50 patients with vitiligo and 38 controls. The type of vitiligo, body surface area (BSA), disease advancement assessment according to Vitiligo European Task Force, the degree of skin involvement and degree of progression were measured. Patients' skin phototype was determined according to Fitzpatrick’s classification. Medical history was recorded. Venous blood samples were obtained, The sera were used for laboratory test. Determinations of IL-17, IL-22 and IL-23 were performed using the enzyme-linked immunoabsorbent assay. In the study group 4 cases had phototype I, 38 II, 8 III. In the control group: 3, 29, 6, respectively. Universal vitiligo was found in 38 patients, segmental in 2, acro-facial in 10. In all cases VETF was + 1. Hypothyroidism was recorded in the medical histories of 11 cases vs 2 controls. Significantly higher concentrations of IL-22 and IL-23 were in cases vs controls. IL-22 concentrations were significantly higher in the study group with BSA ≤ 10 than in the control group, and in the group with BSA ≥ 10 they were the highest (p &lt; 0.05). IL-22 is the best marker of active universal type vitiligo, it is directly proportional to the extent of lesions. [Display omitted] •IL-22 is the best marker of active universal type vitiligo.•IL-23 is elevated in patients with vitiligo.•The concentration of Il-22 is directly proportional to the area of skin affected.</description><subject>Interleukin 17</subject><subject>Interleukin 22</subject><subject>Interleukin 23</subject><subject>Vitiligo</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kL1OwzAYRS0EEqXwBgweWRI-20mcLEhVVX6kSiwwW45jty5JHGynqG9PqjAz3eXeK52D0D2BlAApHg9pbd2wlykFSlNCGC_zC7QgVQ5JAcAv0QJ4zhLGKL1GNyEcACAvWLlAmxVWMuhEuT561-IQx-aEXY9t1429a93OKtxJ_6V9wM7gQUar-xjwj417fLTRtnbnbtGVkW3Qd3-5RJ_Pm4_1a7J9f3lbr7aJYiSPiWyq2lRQGy1B1WDqjNHSZESRumFcFUQqzlmTQWWkITk0spRVViltCg5VXbAleph_B---Rx2i6GxQum1lr90YBOU0z7KcMDZVs7mqvAvBayMGbyeQkyAgztbEQczWxNmamK1Ns6d5pieMo9VeBDUBK91Yr1UUjbP_H_wCvfB4jA</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Nieradko-Iwanicka, Barbara</creator><creator>Przybylska, Daria</creator><creator>Borzęcki, Andrzej</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202212</creationdate><title>A case-control study on immunologic markers of patients with vitiligo</title><author>Nieradko-Iwanicka, Barbara ; Przybylska, Daria ; Borzęcki, Andrzej</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-ad9bf90bfea0cb0fb4328f41c1bd37c61ac773d409faf150da8a949cef6709b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Interleukin 17</topic><topic>Interleukin 22</topic><topic>Interleukin 23</topic><topic>Vitiligo</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nieradko-Iwanicka, Barbara</creatorcontrib><creatorcontrib>Przybylska, Daria</creatorcontrib><creatorcontrib>Borzęcki, Andrzej</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nieradko-Iwanicka, Barbara</au><au>Przybylska, Daria</au><au>Borzęcki, Andrzej</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case-control study on immunologic markers of patients with vitiligo</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><date>2022-12</date><risdate>2022</risdate><volume>156</volume><spage>113785</spage><epage>113785</epage><pages>113785-113785</pages><artnum>113785</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Vitiligo is a depigmentation skin disease often coexisting with other autoimmune disorders. The prevalence is 0.5–2 % of the world's population. A combination of genetic, environmental and biochemical factors play a role in pathogenesis of the disease. The aim of the study was to measure selected cytokines in the blood sera of patients with vitiligo and to select the best marker of the disease. The study was conducted on 50 patients with vitiligo and 38 controls. The type of vitiligo, body surface area (BSA), disease advancement assessment according to Vitiligo European Task Force, the degree of skin involvement and degree of progression were measured. Patients' skin phototype was determined according to Fitzpatrick’s classification. Medical history was recorded. Venous blood samples were obtained, The sera were used for laboratory test. Determinations of IL-17, IL-22 and IL-23 were performed using the enzyme-linked immunoabsorbent assay. In the study group 4 cases had phototype I, 38 II, 8 III. In the control group: 3, 29, 6, respectively. Universal vitiligo was found in 38 patients, segmental in 2, acro-facial in 10. In all cases VETF was + 1. Hypothyroidism was recorded in the medical histories of 11 cases vs 2 controls. Significantly higher concentrations of IL-22 and IL-23 were in cases vs controls. IL-22 concentrations were significantly higher in the study group with BSA ≤ 10 than in the control group, and in the group with BSA ≥ 10 they were the highest (p &lt; 0.05). IL-22 is the best marker of active universal type vitiligo, it is directly proportional to the extent of lesions. [Display omitted] •IL-22 is the best marker of active universal type vitiligo.•IL-23 is elevated in patients with vitiligo.•The concentration of Il-22 is directly proportional to the area of skin affected.</abstract><pub>Elsevier Masson SAS</pub><doi>10.1016/j.biopha.2022.113785</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2022-12, Vol.156, p.113785-113785, Article 113785
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_2725445133
source Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals
subjects Interleukin 17
Interleukin 22
Interleukin 23
Vitiligo
title A case-control study on immunologic markers of patients with vitiligo
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T09%3A07%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case-control%20study%20on%20immunologic%20markers%20of%20patients%20with%20vitiligo&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Nieradko-Iwanicka,%20Barbara&rft.date=2022-12&rft.volume=156&rft.spage=113785&rft.epage=113785&rft.pages=113785-113785&rft.artnum=113785&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2022.113785&rft_dat=%3Cproquest_cross%3E2725445133%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2725445133&rft_id=info:pmid/&rft_els_id=S075333222201174X&rfr_iscdi=true